Design and Development of a Remote Battery Management System This research focuses on the design and development of a battery management system that enables remote monitoring and control, allowing users to customize battery cell properties as needed. The system is specifically designed for use with graphene battery cells and can be effectively applied to alternative energy systems for residential use.
1. เพิ่มประสิทธิภาพการจัดการพลังงาน – ระบบบริหารจัดการแบตเตอรี่ที่สามารถควบคุมและมอนิเตอร์ระยะไกลช่วยให้สามารถจัดการพลังงานได้อย่างมีประสิทธิภาพ ลดการสูญเสียพลังงาน และเพิ่มอายุการใช้งานของแบตเตอรี่ 2. รองรับเทคโนโลยีแบตเตอรี่กราฟีน – แบตเตอรี่กราฟีนมีศักยภาพสูงในการเก็บพลังงานและมีอายุการใช้งานยาวนาน โครงการนี้ช่วยทดสอบและพัฒนาการนำแบตเตอรี่กราฟีนไปใช้ในระบบพลังงานทางเลือก 3. เพิ่มความสะดวกและความปลอดภัยในการใช้งาน – การควบคุมและมอนิเตอร์แบตเตอรี่จากระยะไกลช่วยลดความเสี่ยงจากการเกิดปัญหาทางเทคนิค เช่น การชาร์จไฟเกินหรืออุณหภูมิสูงเกินไป ทำให้ระบบมีความปลอดภัยมากขึ้น 4. ส่งเสริมการพัฒนาเทคโนโลยีภายในประเทศ – โครงการนี้ช่วยสนับสนุนการพัฒนาเทคโนโลยีแบตเตอรี่และระบบบริหารจัดการพลังงานภายในประเทศ ลดการพึ่งพาเทคโนโลยีจากต่างประเทศ และเพิ่มขีดความสามารถในการแข่งขันด้านพลังงาน
คณะอุตสาหกรรมอาหาร
In recent years, many people have shown greater interest in plant-based proteins because of their health benefits and lower impact on the environment. This study will look at the physical and chemical properties of chickpeas and red beans. It will also create a plant-based burger that tastes and feels similar to meat-based burgers while providing comparable nutrition. We will steam the ingredients and then analyze important properties such as texture, color, water activity (aW), pH, and how well they retain water and oil. Additionally, we will conduct a sensory evaluation to understand consumer preferences.
คณะสถาปัตยกรรม ศิลปะและการออกแบบ
In the world of blood donation, there are 2 types of people: those who donate blood and those who don't. Most campaigners emphasize how to persuade more people to donate blood and recruit more new blood donors. We believe that even though such focus is important, there're more critical aspects that might have been neglected, which is: for those who have already made up their minds to be blood doners, will they be successful in donating when the time comes? According to our studies, only 63 % of attempted doners are successful. Regrettably, 37 % has to go home disappointed as their bodies are not fit for the conditions required by Red Cross medical staff at blood donation centers (which include some most basic preparations such as low-fat food intake and 8-hours sleep on the night before). Our campaign, ‘Blood in Need, Buddy Indeed’, focuses on 2 aspects. Firstly, to persuade more people to donate blood. Secondly, for those who have made up their minds to donate blood, we will provide necessary support (both body and mind) so that they are fully prepared and successful in donating blood when the time comes via networks of systems, staffs and the newly designed and prototype of the application ‘Blood D’. Our campaign covers the whole ‘before/during/after’ experience of users (as blood doners). Support includes assessment of their current condition whether they are within the requirement of Red Cross Blood Bank. ‘Blood D’ will also provide relevant information on blood donating events, such as locations, and time booking. Once sign-up, the application “Blood D” will sent friendly reminder and clear infographic on how to prepare their bodies as daily notifications during the 7 days countdown. This is to ensure that the users’ blood will be ‘D’ (homophone of the Thai word ‘ดี’ which mean ‘good’ and at the same time playing on the word ‘ Buddy’) or be the ‘good blood’ that can save lives for those in need. After organizing 4 blood donation events both within and outside the KMITL. The numbers of successful blood doners have increased from 63 % to 78 % (this number is the average of 4 events, with the most successful event of 89%). The campaign has won the first runner up in national blood donation campaign competition. It is highly anticipated that once the application “Blood D” is fully launched, it will help increase the amount of blood collected up to 15% with the same numbers of existing doners.
คณะวิทยาศาสตร์
Cancer remains a major global health challenge as the second-leading cause of human death worldwide. The traditional treatments for cancer beyond surgical resection include radiation and chemotherapy; however, these therapies can cause serious adverse side effects due to their high killing potency but low tumor selectivity. The FDA approved monoclonal antibodies (mAbs) that target TIGIT/PVR (T-cell immunoglobulin and ITIM domain/poliovirus receptor) which is an emerging immune checkpoint molecules has been developed; however, the clinical translation of immune checkpoint inhibitors based on antibodies is hampered due to immunogenicity, immunological-related side effects, and high costs, even though these mAbs show promising therapeutic efficacy in clinical trials. To overcome these bottlenecks, small-molecule inhibitors may offer advantages such as better oral bioavailability and tumor penetration compared to mAbs due to their smaller size. Here, we performed structure-based virtual screening of FDA-approved drug repertoires. The 100 screened candidates were further narrowed down to 10 compounds using molecular docking, with binding affinities ranging from -9.152 to -7.643 kcal/mol. These compounds were subsequently evaluated for their pharmacokinetic properties using ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis, which demonstrated favorable drug-like characteristics. The lead compounds will be further analyzed for conformational changes and binding stability against TIGIT through molecular dynamics (MD) simulations to ensure that no significant conformational changes occur in the protein structure. Collectively, this study represents the potential of computational methods and drug repurposing as effective strategies for drug discovery, facilitating the accelerated development of novel cancer treatments.